In a meta-analysis of l & # 39;Australia, Dr. Kiely and his colleagues analyzed chemotherapy of first line of the randomized controlled trials conducted in patients with metastatic breast cancer, published between 1999 and 2009. We have analyzed the factors of the disease and the patient and the parameters of the survival curves and overall survival (OS) and the survival without progression (PFS) for each test. Each curve obtained following percentiles: (worst case) 90, 75 (low typ), 25 (above normal) and 10 (best). The results showed that the average median PFS was 7.5 months, and the median survival averaged 21.5 months, with a proportion of median PFS d & # 39; almost 3 OS. Means for each business scenario are:

• The worst case (10 percentile), 6.25 months;

• Under typical (percentile 25), 12 months;

• Added Typical (percentile 75), and 36 months

• The best (90 percentile), 56 months.

Simple multiples of the median gave accurate estimates of more than 95% of the OS curves for all scenarios, except for the worse, where simple multiples of the median estimate of 73% accurate.

Point of view

Estimate the survival of metastases is a challenge for physicians. Taking into account the heterogeneity of the disease and patient factors, should provide a potential result not only inform patients and their families, but also to help guide treatment decisions.

This elegant analysis for eligible patients for the treatment of first line tometastatic breast cancerprobably included patients from d & # 39; a State of performance above and below the tumor mass than the average patient of metastatic breast cancer. In addition, many patients who were part of the meta-analysis n & # 39; had not received a standard adjuvant treatment in the community available to patients d & # 39; today & # 39; s, afterinitial diagnosis. Therefore, estimates for the survival of this analysis would be probably higher that in the average population of patients with metastatic breast cancer occur in the community today & # 39; s.

Be able to provide this information as well as the worst case, the median and the best for patients and their families is important to help them plan ahead and make decisions for the treatment and supportive care.

I hope that researchers of these and other works for the same information to doctors for use in palliative situations for example cancer advanced of lung, glioblastoma, cancer of the pancreas advanced, metastatic and other situations.

www.mybased.com is a major topic site about the health and maintenance, such as Fitness and Exercise, Children and Teenagers, Health wellness product, Sexual Health Issues, Health Check Tools, Disorders and Conditions, Digestive System, Cancers , Etc.